Premium
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
Author(s) -
Messinger Yoav,
Gay Paul,
Raetz Elizabeth,
Hutchinson Raymond,
DuBois Steven,
GladeBender Julia,
Sposto Richard,
van der Giessen Jeannette,
Eckroth Elena,
Bostrom Bruce C.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22456
Subject(s) - medicine , bortezomib , dexamethasone , chemotherapy , vincristine , acute lymphocytic leukemia , leukemia , regimen , childhood leukemia , toxicity , asparaginase , oncology , multiple myeloma , cyclophosphamide , lymphoblastic leukemia
Outcomes remain poor for children after relapse of acute lymphoblastic leukemia (ALL), especially after early marrow relapse. Bortezomib is a proteasome inhibitor with in vitro synergy with corticosteroids and clinical activity in human lymphoid malignancies.